Previous 10 | Next 10 |
Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the closing of its previously announced "reasonable best efforts" public...
Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the pricing of its "reasonable best efforts" public offering of 7,333,33...
Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it intends to offer and sell shares of its common stock (or common ...
Appropriate payment amounts received on two MyoPro claims; Additional claims are under review while CMS rulemaking to re-classify the MyoPro to the brace benefit category progresses Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable m...
MyoPro patients win cases against German Statutory Insurance System payers including BARMER, Germany’s second-largest statutory health insurer Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that off...
2023-08-09 18:19:06 ET Myomo, Inc. (MYO) Q2 2023 Earnings Conference Call August 09, 2023 04:30 PM ET Company Participants Kim Golodetz - Investor Relations, LHA Paul Gudonis - Chief Executive Officer Dave Henry - Chief Financial Officer Conference Call Par...
2023-08-09 16:16:23 ET Myomo press release ( NYSE: MYO ): Q2 GAAP EPS of -$0.04 misses by $0.01 . Revenue of $5.96M (+62.0% Y/Y) beats by $0.33M . For further details see: Myomo GAAP EPS of -$0.04 misses by $0.01, revenue of $5.96M beats by $0.33M
Q2 revenue of $6.0 million, including license revenue Nearly 1,000 prospective MyoPro® candidates with known payers in the patient pipeline Begins to build Medicare Part B patient pipeline following publication of proposed rule by the Centers for Medicare and Medicaid Service...
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for th...
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that management will be participating in the Maxim...
News, Short Squeeze, Breakout and More Instantly...
2024-07-10 17:00:05 ET Scott Henry from Industrial Alliance Securities issued a price target of $5.75 for MYO on 2024-07-10 15:33:00. The adjusted price target was set to $5.75. At the time of the announcement, MYO was trading at $4.97. The overall price target consensus...
2024-07-10 16:15:02 ET Alliance Global Partners analyst issues BUY recommendation for MYO on July 10, 2024 03:33PM ET. The previous analyst recommendation was Buy. MYO was trading at $4.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...
2024-07-09 10:30:11 ET Lake Street analyst issues BUY recommendation for MYO on July 9, 2024 08:45AM ET. The previous analyst recommendation was Buy. MYO was trading at $4.07 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst...